Daptomycin Vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Last updated: November 25, 2024
Sponsor: Todd C. Lee MD MPH FIDSA
Overall Status: Active - Recruiting

Phase

4

Condition

Sepsis And Septicemia

Soft Tissue Infections

Cardiovascular Disease

Treatment

Vancomycin (IV)

Daptomycin for Injection

Clinical Study ID

NCT06637332
2025-10666
466322
  • Ages > 18
  • All Genders

Study Summary

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Eligibility Criteria

Inclusion

The participant must meet all inclusion and exclusion criteria for the SNAP Platform

Exclusion

(NCT05137119) and also the following inclusion and exclusion criteria:

Inclusion Criteria:

  • Methicillin-resistant S. aureus bacteremia

Exclusion Criteria:

  • Severe allergy or non-severe rash to vancomycin or daptomycin

  • Suspected or confirmed MRSA pneumonia

  • Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L

Study Design

Total Participants: 300
Treatment Group(s): 2
Primary Treatment: Vancomycin (IV)
Phase: 4
Study Start date:
November 14, 2024
Estimated Completion Date:
November 30, 2027

Connect with a study center

  • Fraser Health Authority (Surrey Memorial Hospital)

    Surrey, British Columbia V3V1Z2
    Canada

    Active - Recruiting

  • McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

    Montreal, Quebec H4A3S1
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.